AVI BioPharma names chief executive
Chris Garabedian joins US biopharmaceutical firm from Celgene
Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.
Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.
He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.
‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.
You may also like
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Neuland Laboratories announces new $20m process development lab in Hyderabad]()
Neuland Laboratories announces new $20m process development lab in Hyderabad
The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Regulatory
![FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs]()
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs
GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually
Pharmaceutical
![Maximising product recovery with a GFD filter dryer removable basket]()
Maximising product recovery with a GFD filter dryer removable basket
Product value is often inversely proportional to volume in pharmaceutical R&D and kilo-lab production. When synthesising a few hundred grams of a novel drug candidate, every milligram can represent weeks of experimentation, costly reagents, and the potential success of a clinical trial
Pharmaceutical
![How pressure and vacuum filtration in ANFDs improves yield]()
How pressure and vacuum filtration in ANFDs improves yield
During solid-liquid separation in industries such as pharmaceuticals and fine chemicals, both process efficiency and product quality are critical requirements. Effective use of pressure and vacuum filtration can help address this in downstream processing